Literature DB >> 11432887

Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas.

F C Eilber1, G Rosen, J Eckardt, C Forscher, S D Nelson, M Selch, F Dorey, F R Eilber.   

Abstract

PURPOSE: To determine whether treatment-induced pathologic necrosis correlates with local recurrence and overall survival in patients who receive neoadjuvant therapy for high-grade extremity soft tissue sarcomas. PATIENTS AND METHODS: Four hundred ninety-six patients with intermediate- to high-grade extremity soft tissue sarcomas received protocol neoadjuvant therapy. All patients underwent surgical resection after neoadjuvant therapy and had pathologic assessment of tumor necrosis in the resected specimens.
RESULTS: The 5- and 10-year local recurrence rates for patients with > or = 95% pathologic necrosis were significantly lower (6% and 11%, respectively) than the local recurrence rates for patients with less than 95% pathologic necrosis (17% and 23%, respectively). The 5- and 10-year survival rates for the patients with > or = 95% pathologic necrosis were significantly higher (80% and 71%, respectively) than the survival rates for the patients with less than 95% pathologic necrosis (62% and 55%, respectively). Patients with less than 95% pathologic necrosis were 2.51 times more likely to develop a local recurrence and 1.86 times more likely to die of their disease as compared with patients with > or = 95% pathologic necrosis. The percentage of patients who achieved > or /= 95% pathologic necrosis increased to 48% with the addition of ifosfamide as compared with 13% of the patients in all the other protocols combined.
CONCLUSION: Treatment-induced pathologic necrosis is an independent predictor of both local recurrence and overall survival in patients who receive neoadjuvant therapy for high-grade extremity soft tissue sarcomas. A complete pathologic response (> or = 95% pathologic necrosis) correlated with a significantly lower rate of local recurrence and improved overall survival.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11432887     DOI: 10.1200/JCO.2001.19.13.3203

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  78 in total

1.  Neoadjuvant radiation in primary extremity liposarcoma: correlation of MRI features with histopathology.

Authors:  Jeremy R Wortman; Sree Harsha Tirumani; Harika Tirumani; Atul B Shinagare; Jyothi P Jagannathan; Jason L Hornick; Nikhil H Ramaiya
Journal:  Eur Radiol       Date:  2015-08-28       Impact factor: 5.315

2.  Preoperative chemotherapy for soft tissue sarcomas: reinventing the wheel.

Authors:  Gerald Rosen
Journal:  Skeletal Radiol       Date:  2008-07       Impact factor: 2.199

3.  Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.

Authors:  Emily Z Keung; Jen-Wei Tsai; Ali M Ali; Janice N Cormier; Andrew J Bishop; B Ashleigh Guadagnolo; Keila E Torres; Neeta Somaiah; Kelly K Hunt; Jennifer A Wargo; Alexander J Lazar; Wei-Lien Wang; Christina L Roland
Journal:  Oncoimmunology       Date:  2017-10-31       Impact factor: 8.110

4.  Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma.

Authors:  William W Tseng; Shouhao Zhou; Christina A To; Peter F Thall; Alexander J Lazar; Raphael E Pollock; Patrick P Lin; Janice N Cormier; Valerae O Lewis; Barry W Feig; Kelly K Hunt; Matthew T Ballo; Shreyaskumar Patel; Peter W T Pisters
Journal:  Cancer       Date:  2015-07-15       Impact factor: 6.860

5.  Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?

Authors:  René Adam; Gerard Pascal; Denis Castaing; Daniel Azoulay; Valerie Delvart; Bernard Paule; Francis Levi; Henri Bismuth
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

Review 6.  Musculoskeletal tumors: how to use anatomic, functional, and metabolic MR techniques.

Authors:  Laura M Fayad; Michael A Jacobs; Xin Wang; John A Carrino; David A Bluemke
Journal:  Radiology       Date:  2012-11       Impact factor: 11.105

7.  Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.

Authors:  Robert J Canter; Dariusz Borys; Abimbola Olusanya; Chin-Shang Li; Li-Yuan Lee; Robert D Boutin; Scott D Christensen; Robert M Tamurian; Arta M Monjazeb
Journal:  Ann Surg Oncol       Date:  2014-02-20       Impact factor: 5.344

8.  A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas.

Authors:  Jörg Thomas Hartmann; M Horger; T Kluba; A Königsrainer; P de Zwart; C Hann von Weyhern; F Eckert; W Budach; C Bokemeyer
Journal:  Invest New Drugs       Date:  2013-10-04       Impact factor: 3.850

Review 9.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.

Authors:  Douglas S Hawkins; Sheri L Spunt; Stephen X Skapek
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

10.  The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.

Authors:  Fritz C Eilber; Frederick R Eilber; Jeffery Eckardt; Gerald Rosen; Elyn Riedel; Robert G Maki; Murray F Brennan; Samuel Singer
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.